Readings — From the September 2017 issue
Public Enemy
Download Pdf
Read Online
SIGN IN to access Harper’s Magazine
Need to create a login? Want to change your email address or password? Forgot your password?
1. Sign in to Customer Care using your account number or postal address.
2. Select Email/Password Information.
3. Enter your new information and click on Save My Changes.
Subscribers can find additional help here. Not a subscriber? Subscribe today!
From the jury selection process that took place over three days in June for the trial of Martin Shkreli, an investor and hedge fund founder who is facing eight counts of securities and wire fraud. In 2015, when Shkreli was CEO of Turing Pharmaceuticals, the company raised the price of its drug Daraprim by 5,000 percent. In 2016, Shkreli was widely criticized for defending the 400 percent increase in the price of EpiPen, an emergency allergy injection sold by Mylan. More than two hundred potential jurors were excused from the trial. Judge Kiyo Matsumoto presided. Benjamin Brafman is a lawyer representing Shkreli.
You are currently viewing this article as a guest. If you are a subscriber, please sign in.
If you aren't, please subscribe below and get access to the entire Harper's archive for only $45.99/year.
Or purchase this issue on your iOS or Android devices for $6.99.
SIGN IN to access Harper’s Magazine
Need to create a login? Want to change your email address or password? Forgot your password?
1. Sign in to Customer Care using your account number or postal address.
2. Select Email/Password Information.
3. Enter your new information and click on Save My Changes.
Subscribers can find additional help here. Not a subscriber? Subscribe today!
© 2017 Harper’s Magazine Foundation. Cover: Illustration by John Ritter. Source photographs (details): © Kevork Djansezian/AP Photo; © Wally Santana/AP Photo
Sign up to receive The Weekly Review, Harper’s Magazine’s singular take on the past seven days of madness. It’s free!*
*Click “Unsubscribe” in the Weekly Review to stop receiving emails from Harper’s Magazine.
